Kimberly Blackwell - Nov 1, 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Stock symbol
ZNTL
Transactions as of
Nov 1, 2021
Transactions value $
-$32,660
Form type
4
Date filed
11/2/2021, 07:24 PM
Previous filing
Oct 27, 2021
Next filing
Dec 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Options Exercise $47.8K +1K +20% $47.80 6K Nov 1, 2021 Direct F1
transaction ZNTL Common Stock Sale -$80.5K -1K -16.67% $80.46 5K Nov 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Options Exercise $0 -1K -2.44% $0.00 40K Nov 1, 2021 Common Stock 1K $47.80 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2021.
F2 The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant, July 1, 2020.